Micronized Dehydrated Human Amniotic Membrane (dHACM) Suspension in the Treatment of Lateral Epicondylitis.
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 5
- 试验地点
- 1
- 主要终点
- Proportion of patients achieving improvement in ASES elbow score in the dHACM treatment group vs the control group.
研究概览
简要总结
The purpose of this study is to determine whether micronized dehydrated human amniotic membrane (dHACM) suspension is more effective in reducing inflammation than conservative measures alone when used to treat acute/early lateral epicondylitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •At least 18 years old.
- •Medicare patients may be selected.
- •Both male and female patients will be selected.
- •A negative x-ray of the elbow
- •Diagnosis of lateral epicondylitis by history and exam with symptoms for no longer than one year.
- •Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
- •Patient understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
- •Patient has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.
排除标准
- •Prior surgery at the site
- •Site exhibits clinical signs and symptoms of infection.
- •History of chronic soft tissue inflammation of more than 6 months.
- •A positive X-ray for fracture or significant anatomic abnormality including fracture, advanced arthritis, excessive calcification, etc.
- •No history of corticosteroid injection within the past 30 days.
- •Joint instability
- •No rheumatologic conditions involving the elbow.
- •No evidence of significant neurological entrapment or neurological disease of the forearm
- •Concurrent cervical radiculopathy
- •The presence of comorbidities that can be confused with or can exacerbate the condition including:
- •Previous elbow trauma
- •Previous elbow surgery
- •Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study. (i.e. a one month "washout period" for these drugs.)
- •Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening.
- •History of radiation at the site.
- •Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
- •Patients who are unable to understand the aims and objectives of the trial.
- •Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
- •Pregnant or breast feeding. No pregnancy within the past 6 months.
研究组 & 干预措施
dHACM
Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
干预措施: Standard of Care Therapy (Behavioral)
dHACM
Standard of Care Therapy plus dHACM injection at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
干预措施: dHACM Injection (Other)
Saline Injection
Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
干预措施: Standard of Care Therapy (Behavioral)
Saline Injection
Standard of Care Therapy plus normal saline injection instead of active agent at initial visit, to be repeated if symptoms persist at the time of week 4 and week 8 follow up visits.
干预措施: Normal Saline Injection (Other)
结局指标
主要结局
Proportion of patients achieving improvement in ASES elbow score in the dHACM treatment group vs the control group.
时间窗: 12 weeks
次要结局
- Proportion of patients achieving improvement in range of motion in the dHACM treatment group vs the control group.(12 weeks)